A recent study reveals that individuals who come off blockbuster slimming jabs like Mounjaro or Wegovy can put back on reduced body mass far faster than those who halt traditional lifestyle programs.
Published data in a prominent health publication shows that while overweight individuals often shed substantial amounts of their body weight while undergoing treatment, the mass returns at an estimated rate of nearly a kilo each month once they quit.
"People purchasing such medications need to be informed of the potential of rapid weight regain when the treatment is stopped," stated expert Dr. Susan Jebb.
This pace of regain suggests a return to starting mass in about a year and a half.
Comparing Approaches
The research, which looked at 37 of studies involving thousands of participants, compared the effects of GLP-1 agonists with other pills.
Researchers emphasize that people who shed pounds through lifestyle changes alone usually see a slower creep back—approximately 100 grams monthly—after stopping.
The Reason for the Fast Rebound
Doctors propose the mechanism of the jabs is key to understanding the heightened weight return.
These medications copy a natural hormone called GLP-1, which controls appetite.
"Artificially providing the hormone concentrations far above than the body's typical production might result in the body to produce less of its own natural hormone, and may also diminish responsiveness to its actions," said Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this GLP-1 'fix' leads to appetite is uncontrolled, making binge eating far more likely."
A Chronic Disease?
Medical guidelines recommend the injections for people with obesity-related health risks, alongside recommended diet and exercise modifications.
Many experts say that, considering the high risk of relapse, the treatment is often life-long.
This opinion is supported by pharmaceutical companies, who state that the findings "underscore the long-term character of excess weight," akin to managing conditions like diabetes.
User Accounts
Users who have discontinued the jabs report a intense return of appetite.
"It felt as if a trigger flipping and I was suddenly ravenous," described a patient.
This difficulty is worsened if individuals have not established sustainable lifestyle or habit changes during treatment.
Significant Interest
Survey data suggest that a significant number of adults in the UK have tried weight-loss jabs in the past year, with interest continuing to grow.
- Adoption is higher among females compared to men.
- The middle-aged demographic shows the greatest usage rates.
- Many obtain the drugs through private healthcare rather than public health services.
In conclusion, experts stress that while GLP-1 drugs are effective agents for shedding pounds, they are not a standalone solution and maintained weight loss relies on ongoing behavioural support.
